| 0.9611 0.071 (7.99%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.37 |
1-year : | 1.6 |
| Resists | First : | 1.17 |
Second : | 1.37 |
| Pivot price | 0.92 |
|||
| Supports | First : | 0.89 |
Second : | 0.72 |
| MAs | MA(5) : | 0.83 |
MA(20) : | 0.95 |
| MA(100) : | 1.51 |
MA(250) : | 1.88 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 37.5 |
D(3) : | 20.2 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 3.22 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ WALD ] has closed below upper band by 42.7%. Bollinger Bands are 12.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.04 - 1.05 | 1.05 - 1.05 |
| Low: | 0.85 - 0.86 | 0.86 - 0.86 |
| Close: | 0.95 - 0.96 | 0.96 - 0.97 |
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Sat, 02 May 2026
Waldencast PLC (NASDAQ:WALD) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Thu, 30 Apr 2026
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin* - GlobeNewswire
Wed, 29 Apr 2026
Waldencast Stock Steadies As SEC Closes Probe On Obagi Accounting - timothysykes.com
Tue, 28 Apr 2026
Waldencast announces conclusion of SEC investigation - The Daily Tribune News
Tue, 28 Apr 2026
Waldencast Clears SEC Probe Over Obagi-Related Accounting Issues - TipRanks
Tue, 28 Apr 2026
Waldencast announces conclusion of SEC investigation - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 118 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 55.6 (%) |
| Held by Institutions | 26.1 (%) |
| Shares Short | 972 (K) |
| Shares Short P.Month | 746 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.91 |
| Profit Margin | -84.5 % |
| Operating Margin | -22.5 % |
| Return on Assets (ttm) | -4.8 % |
| Return on Equity (ttm) | -40.4 % |
| Qtrly Rev. Growth | -1.8 % |
| Gross Profit (p.s.) | 1.54 |
| Sales Per Share | 2.3 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | 115 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 0.24 |
| Price to Sales | 0.41 |
| Price to Cash Flow | -8.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|